One significant advantage of bispecific TCRs is their ability to target "undruggable" proteins. Many cancer-associated proteins reside inside cells, making them inaccessible to therapies that target surface antigens. Bispecific TCRs can recognize peptide fragments of these proteins presented on the cell surface by HLA molecules, potentially expanding the range of targetable cancers. Moreover, bispecific TCRs can be designed to have high affinity for tumor antigens while maintaining specificity, which minimizes off-target effects and reduces the risk of damage to healthy tissues.
